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g.2013.0Abstract The present study investigated the relationship between the genetic polymorphisms in
MMP-9 and MMP-3 genes and acute myocardial infarction (AMI). We examined 40 patients with
acute myocardial infarction and 40 age and sex matched controls for MMP-9 functional promoter
polymorphism (1562 C > T) and MMP-3 (5A/6A) deletion/insertion polymorphism using restric-
tion fragment length polymorphism (RFLP) for ampliﬁed genomicDNA.The frequencies of the com-
bined mutant genotypes CT and TT in the (1562 C > T) MMP9 were signiﬁcantly higher in AMI
patients (20%) when compared to the controls (0%) (p value = 0.005) showing an association
between these genotypes and AMI. Also there was a signiﬁcant difference between 5A/5A genotype
and 5A allele frequencies when both are compared in the patients (25% and 35%) and the controls
(2.5% and 18.75%) (p= 0.009; OR = 13; CI = 1.576–107.233); and (p= 0.02; OR = 2.333,
CI = 1.130–4.820) respectively. In conclusion, the 1562C > T polymorphism of the MMP9 gene
is strongly associated with acute myocardial infarction in the Egyptian population. Furthermore,
our study supported the presence of the 5A/5A genotype of MMP3 gene promoter polymorphism
as a risk factor of AMI in Egyptian patients.Meanwhile, the race selection should be paid more atten-
tion since the pathogenesis of a diseasemight have different bases in different racial population groups.
 2013 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved., Mekias Street, Manial El
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1.0051. Introduction
Myocardial infarction is caused by several inherited and ac-
quired risk factors that predispose to the development of ath-
erosclerotic lesions and plaque rupture. This rupture of an
atherosclerotic plaque is a major event in the pathogenesis of
an acute myocardial infarction (AMI) [1]. Plaques that areier B.V. All rights reserved.
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tous core, a thin ﬁbrous cap covering the core, active inﬂam-
matory cellular inﬁltration, particularly in the plaque
shoulders affected by strong shear stress, and reduced smooth
muscle cell density collagen content in the ﬁbrous cap. Matrix
metalloproteinases (MMPs), mainly produced by inﬁltrating
cells, degrade the extracellular matrix, thereby contributing
to the weakening of the cap and its subsequent rupture [2].
MMPs are a family of more than 20 zinc-dependent protein-
ases with proteolytic activity against extracellular matrix
(ECM) components including collagen and elastin, as well as
numerous proteins involved in angiogenesis, cell migration,
growth and apoptosis [3]. Each MMP has distinct although
overlapping substrate speciﬁcities. Previous studies have sug-
gested that MMPs may play a role in cardiovascular and cere-
brovascular diseases [4].
Of the many matrix metalloproteinases, MMP-9 (gelatinase
B) might play an important role in matrix degradation and the
subsequent rupture of the atherosclerotic plaques, owing to its
broad substrate speciﬁcity distal position in the matrix proteo-
lytic cascade. MMP-9 is involved in the degradation of a broad
spectrum of substrates, including collagen types IV, V, VII and
X as well as gelatin, and also degrades the proteoglycans and
the elastins [5]. A functional single nucleotide polymorphism
(SNP) in the MMP-9 promoter, with a cytosine to thymidine
transition at position -1562, was found. According to in vitro
assays of the promoter activity, the T allele had a higher pro-
moter activity than the C allele [6], and was associated with an
elevation in both the levels of MMP-9 expression level and ser-
um MMP-9 in humans. An association of a SNP in the MMP-
9 promoter with coronary artery disease and risk of myocar-
dial infarction lesions has also been reported [7].
Stromelysin is a metalloproteinase (MMP-3) involved in the
turnover of the extracellular matrix components. This enzyme
exhibits a wide spectrum of activity: it is able to degrade pro-
teoglycans, collagens III, IV, V, and IX, laminin, ﬁbronectin,
gelatin, and elastin. MMP-3 has been found to be extensively
expressed in atherosclerotic plaques by macrophage origin
and smooth muscle cells in the plaque cap, intima, and adven-
titia [8]. This ﬁnding has led to the hypothesis that MMP-3
might be involved in plaque rupture, followed by platelet acti-
vation and initiation of the coagulation cascade [9]. The pro-
moter of human MMP3 contains a common deletion/
insertion polymorphism, characterized by runs of 5 or 6 ade-
nosines, 1612 bp upstream from the start site of transcription
(rs3025058, also known as 5A/6A polymorphism) [10]. The
aim of the present study was to investigate whether polymor-
phisms in MMP-9 and MMP-3 genes are a signiﬁcant risk fac-
tor for acute myocardial infarction in an Egyptian Cohort.
2. Subjects and method
2.1. Study design
Case-control study both descriptive and analytic.
2.2. Subjects
The study was carried out in accordance with the Helsinki
Declaration. The study was approved by the ethics committee
of Faculty of Medicine, Cairo University.This study was conducted on 40 unrelated Egyptian pa-
tients presenting with acute myocardial infarction (AMI) and
40 healthy Egyptian control subjects age and sex matched.
All patients were recruited from the Intensive Care Unit
Department, Cairo University Hospital during the period from
April 2012 to October 2012. Consents were taken from all par-
ticipants before being involved in the study.
Patients were diagnosed as having AMI according to the
World Health Organization criteria and the Consensus Docu-
ment of the Joint European Society of Cardiology/American
College of Cardiology Committee for the Redeﬁnition of a
Myocardial Infarction [11].
2.3. Method
2.3.1. Patients were subjected to the following
(1) History taking and clinical assessment.
(2) Twelve lead electrocardiogram (ECG) to conﬁrm the
diagnosis of ST elevation in MI.
(3) Laboratory investigations including; CK, CK-MB,
LDH, Troponin, AST, ALT and creatinine.
(4) Polymerase chain reaction, restriction fragment length
polymorphism (RFLP) for the detection of MMP9
1562C > T and MMP3 5A/6A polymorphisms.
2.3.2. DNA extraction
Genomic DNA was isolated from 2 ml venous blood sample
withdrawn on EDTA using genomic DNA puriﬁcation kit
(Fermentas) according to the manufacturer’s instructions.
2.3.3. Genotyping
Gene polymorphisms were detected through PCR ampliﬁca-
tion followed by digestion using restriction endonuclease en-
zymes for RFLP analysis. The genotyping of MMP-9
promoter at position 1562 was detected by using the forward
primer, (50-GCC TGG CAC ATA GTA GGC CC-30) corre-
sponding to segment from base pair number (1871 to
1851) and the reverse primer, (50-CTT CCT AGC CAG
CCG GCA TC-30) corresponding to segment from base pair
number (1339 to 1319), as previously described [12].
MMP3 gene 5A/6A polymorphism was genotyped using the
forward primer (50-GGT TCT CCA TTC CTT TGA TGG
GGG GAA AgA-30); and the reverse primer (50-CTT CCT
GGA ATT CAC ATC ACT GCC ACC ACT-30), as previ-
ously described [13]. The second nucleotide A in the forward
primer 30 end was substituted by G in order to facilitate change
in the 5A allele and generate the recognition sites for Psy I
(Tth111 I) (GACN/NNGTC).
PCR reaction for both polymorphisms was performed in a
25 ll volume with 5 ll DNA (50 ng), 1 ll forward primer and
1 ll reverse primer (the primer concentration was 20 pmol for
each primer), 12.5 ll master mix (Dreamtaq Green PCR, Fer-
mentas) and 5.5 ll nuclease free water. Ampliﬁcation was per-
formed on an automated thermal cycler (Applied Biosystems,
USA). PCR conditions for MMP 9 polymorphism were;
5 min for initial denaturation at 94 C; 35 cycles at 94 C for
15 s for denaturation, 30 s at 62 C for annealing and 30 s at
72 C for extension, followed by 8 min at 72 C for ﬁnal exten-
sion [14]. PCR conditions for MMP 3 polymorphism were;
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for 30 s at 94 C, 30 s annealing at 65 C, and 1 min extension
at 72 C, followed by ﬁnal extension at 72 C for 10 min [13].
2.3.4. Restriction enzyme digestion
2.3.4.1. MMP-9. The PCR products were digested with SphI
restriction endonuclease (Fast Digest, Thermo Scientiﬁc) and
subjected to electrophoresis on a 2% agarose gel and the bands
were visualized by ethidium bromide staining under U/V light.
The PCR product of 1562 C allele is not cleaved by SphI,
while that of the 1562 T allele is cleaved by the enzyme gen-
erating 247 and 188 bp fragments [15] (Fig. 1).Figure 1 PCR-RFLP analysis of 1562C>T MMP-9 poly-
morphism in our study. Lane 1: 50 bp DNA molecular weight
marker (Qiagen, USA), Lanes 2 and 3: show CC genotype (435).
Lane 4: shows TT genotype (247 and 188 bp).
Figure 2 PCR-RFLP analysis of 5A/6A MMP-3 polymorphism
in our study. Lane 1: 50 bp DNA molecular weight marker
(Qiagen, USA). Lane 2: shows 5A/5A genotype (97 bp). Lane 3:
shows 5A/6A genotype (130 and 97 bps). Lane 4: shows 6A/6A
genotype (130 bps).2.3.4.2. MMP-3. The PCR product was digested with Psy I
(FastDigest, Thermo Scientiﬁc) The 6A/6A genotype has no
restriction sites, producing therefore one 130 bp band after
digestion; in the 5A/6A genotype only the 5A allele is cut,
showing three bands: 130 bp, 97 bp, 33 bp; in 5A/5A genotype
both alleles are cut into two bands: 97 bp and 33 bp, although
only the 97 bp can be seen on the gel [13] (Fig. 2).
2.4. Statistical methods
Data were statistically described in terms of mean ± standard
deviation (±SD), range, or frequencies (number of cases) and
percentages when appropriate. Comparison of numerical vari-
ables between the study groups was done using the Mann
Whitney U test for independent samples when comparing 2
groups and the Kruskal Wallis test when comparing more than
2 groups. For comparing categorical data, the Chi square (v2)
test was performed. The Exact test was used instead when the
expected frequency is less than 5. Odds ratio (OR) and 95%
conﬁdence interval (95%CI) were calculated for all studied
5A/6A polymorphism haplotypes and alleles between cases
and controls. p values less than 0.05 were considered statistically
signiﬁcant. All statistical calculations were done using com-
puter programs SPSS (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL,USA) version 15 forMicrosoftWindows.
3. Results
3.1. Characteristics of the study participants
This study included two groups; Group I: patients with acute
myocardial infarction (n= 40) including 9 (22.5%) females
and 31 (77.5%) males with an age range of 35 to 67 years
and a median of 53.5 years, [the patients’ group was further
sub-divided into 2 sub-groups according to age >50 years
n= 27(67.5%) and 650 years n= 13 (32.5%)]. Group II:
control group (n= 40). Table 1 shows the laboratory data
of the patients.
3.2. MMP9 1562C > T and MMP3 5A/6A polymorphisms and
AMI
The genotype and allele frequencies of the 1562C > T and
the 5A/6A polymorphisms in the 40 AMI patients and 40 con-
trols were compared (Table 2).
3.2.1. MMP9
3.2.1.1. Genotypes.
 CC genotype: a higher representation of the CC geno
type was found among the control group as compared
to the patients’ group (Table 2).
 CT and TT genotypes: a statistically signiﬁcant differ-
ence was present on comparing the patients’ group
and the control group as the CT or TT genotypes were
only present in the patients (p= 0.005), (Table 2).
3.2.1.2. Alleles
 C allele: a higher representation was present on the
control group (Table 2).
Table 2 Genotyping of MMP-9 1562C > T and MMP-3 5A/6A polymorphism and their allele frequency in the 2 studied groups.
Gene AMIa patients Control group P valuec
MMP-9 1562C > T nb=40 n= 40
CC n (%) 32 (80%) 40 (100%) 0.005
CT+ TT n (%) 8 (20%) 0 (0%)
Allele frequency
C 71 (88.75) 80 (100%) 0.006
T 9 (11.25) 0
MMP-3 5A/6A polymorphism n= 40 n= 40
5A5A n (%) 10 (25%) 1 (2.5%) 0.009
5A6A n (%) 8 (20%) 13 (32.5%) 0.204
6A6A n (%) 22 (55%) 26 (65%) 0.361
Allele frequency
5A 28 (35%) 15 (18.75%) 0.02
6A 52 (55%) 65 (81.25%)
a AMI; acute myocardial infarction.
b n= number.
c p value < 0.05 = signiﬁcant.
Table 1 Laboratory data of patients.
Parameter AMIagroup (n= 40)
Range Normal range Mean ± SD
Cardiac enzymes
CK U/L 531–6562 0–206 1.8 ± 1.4
CK-MB U/L 421–1575 0–38 835.9 ± 314.5
LDH U/L 195–7838 40–150 1681.1 ± 1570.8
AST U/L 81–4670 5–35 545.5 ± 1.1
Troponin positive In all patients
ALT U/L 18–3490 5–35 310.8 ± 783.9
Creatinine mg/dl 0.5–3.2 0.2–1.2 1.2 ± 0.668
a AMI; acute myocardial infarction.
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trols we had a statistically signiﬁcant difference as
the T allele was only present in the patients’ group
(p= 0.006) (Table 2).
3.2.2. MMP3
3.2.2.1. Genotypes.
 5A5A genotype: a statistically signiﬁcant higher repre-
sentation of the 5A5A genotype was found among the
patients’ group as compared to the control group
(p= 0.009;OR= 13;CI = 1.576–107.233), (Tables 2
and 3).
 5A6A genotype: the 5A6A genotype was underrepre-
sented in the patients’ group when compared to the
control group (Tables 2 and 3).
 6A6A genotype: a higher representation of the 6A6A
genotype was present in the control group (Tables 2
and 3).
3.2.2.2. Alleles
 5A allele: a statistically signiﬁcant higher level was
present in the patients group when compared to thecontrol group (p= 0.02; OR= 2.333; CI = 1.130–
4.820), (Tables 2 and 3).
 6A allele: a higher representation of 6A allele was pres-
ent in the control group.
Relation of risk factors to 1562C > T and the 5A/6A
genotypes is shown in Table 4. There was no statistically signif-
icant association between the different variables and
1562C > T or the 5A/6A genotypes. Also there was no asso-
ciation between the values of different studied laboratory
parameters (CK, CK-MB, LDH, AST, ALT, creatinine) and
MMP3 or MMP9 polymorphisms’ genotypes p
valueP 0.05Table 4.
4. Discussion
This study showed that the 1562C > T polymorphism in the
promoter region of MMP-9 gene has a signiﬁcant role in the
development of an acute myocardial infarction. Comparison
of genotypes and allele frequencies between patients and con-
trols was highly signiﬁcant (p value = 0.005 and 0.006, respec-
tively) and showed an increased risk of development of MI
among CT + TT genotypes as well as T allele carriers. Simi-
larly Zhi et al. [16] found that CT/TT genotypes and T allele
Table 3 Odds ratio (OR) of genotype and allele frequency of MMP3 polymorphism calculated on comparing patients with control
group.
Genotype Cases n(%) Controls n(%) ORa 95%CIb OR P valuec
Upper Lower
5A5A 10 (25%) 1 (2.5%) 13.000 107.233 1.576 0.009
5A6A 8 (20%) 13 (32.5%) 0.519 1.438 0.187 0.204
6A6A 22 (55%) 26 (65%) 0.658 1.619 0.268 0.361
Allele
5A 28 (35%) 15 (18.75 %) 2.333 4.820 1.130 0.02
a OR; odds ratio.
b CI; conﬁdence interval.
c p value < 0.05 = highly signiﬁcant.
Table 4 Association between genotypes in the studied polymorphisms and different clinical data.
Variable MMP-9 1562C> T P value MMP-3 5A/6A polymorphism P value
CC CT + TT 5A/5A 5A/6A 6A/6A
Age
>50 years 21(65.6%) 6(75%) 1.0 5 (50%) 6(75%) 16(72.7%) 0.39
50 +<50 years 11(34.4%) 2(25%) 5(50%) 2(25%) 6(27.3%)
Sex
Female 8(25%) 1(12.5%) 0.65 4(40%) 1(12.5%) 4(18.2%) 0.29
Male 24(15%) 7(87.5%) 6(60%) 7(87.5%) 18(81.5%)
Hypertension
Absent 7(21.9%) 0(0.0%) 0.31 2(20%) 2(25%) 3(13.6%) 0.74
Present 25(78.1%) 8(100%) 8(80%) 6(75%) 19(86.4%)
Diabetes
Absent 23(71.9%) 8(100%) 0.16 8(80%) 6(75%) 17(77.3) 0.97
Present 9(28.1) 0(0%) 2(20%) 2(25%) 5(22.7%)
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onary artery disease patients [16]. Also Wang et al. [17] re-
ported an association of the CT and the TT genotypes of
MMP-9 polymorphism with the susceptibility to MI in the
Uighur population of Xinjiang (China) [17].
Recently a meta-analysis by Wang et al. [18] including 18
potentially eligible articles tried to ﬁnd an answer as to
whether MMPs polymorphisms increase the risk of MI. This
meta-analysis demonstrated that the MMP-9 1562C > T
polymorphism is a risk factor associated with increased
MI susceptibility (p= 0.02; OR= 1.14; 95%CI = 1.02–
1.27), but this associations vary in different ethnic popula-
tions [18].
It was biologically acceptable that the variant allele of
1562 C > T polymorphism might increase the expression
of MMP-9 by binding to the transcriptional repressor factor
in the promoter [19] and the overexpression of MMP-9 was
found in human atherosclerotic plaques and involved in rup-
ture of the plaques [20]. This ﬁnding is similar to the results of
a case-control study in a Korean population reporting that
the 1562C > T polymorphism has a signiﬁcant association
with the development of MI [21]. Another autopsy study also
reported that 1562T variant genotypes were related to the
increased risk of MI signiﬁcantly [22]. These results suggest
that the MMP-9 1562C > T polymorphism may play an
important role in the development of MI due to plaque
rupture.Concerning the MMP3 5A/6A polymorphism; 5A/5A
genotype was over represented in patients as compared to con-
trols with a 13-fold increased risk of developing MI
(p= 0.009; OR = 13; CI = 1.576–107.233). A recent meta-
analysis on the relation of MMP3 5A6A polymorphism and
MI, supported the association of the 5A allele with MI [18].
On the contrary, our data were different from a German case
control study [23] which did not support the presence of an
association between individual polymorphisms and haplotypes
of MMP3 with MI. In addition, this study also performed a
meta-analysis of the relationship of 5A/6A MMP3 polymor-
phism and coronary artery diseases using data obtained from
their samples and those from available case-control studies,
the results of the meta-analysis were also incompatible with
a relationship of 5A/6A polymorphism in the MMP3 promoter
region and atherosclerotic diseases of the coronary arteries. In
subgroup analyses, evidence was obtained to suggest different
risk effects of 5A/6A polymorphism between populations of
European descent and East Asians (Japanese and Chinese)
[23] The combination of samples from Europe and East Asia
contributed signiﬁcantly to the high degree of heterogeneity
across studies. This ethnicity-related heterogeneity may reﬂect
the striking differences that exist in the allele frequencies of
5A/6A MMP3 polymorphism between populations of whites
and other ethnic groups. There is evidence for the action of po-
sitive selection, beginning approximately 24,000 years ago,
increasing the frequency of the 5A allele to an average of
148 N.I Sewelam et al.50% in Europe but not elsewhere, including East Asia where
the frequency of the 5A allele is on average 15% [24].
In conclusion, this study supported the association of a
functional polymorphism in the promoter region of the
1562C > T of the MMP9 gene and AMI in the Egyptian
population. Further study on a larger population will be
required to conﬁrm this polymorphism as a potential novel ge-
netic marker for a plaque rupture in Egyptians. Similarly, our
study supported the presence of the 5A/5A genotype of MMP3
gene promoter as a risk factor of AMI in Egyptian patients.
Meanwhile, the race selection should be paid more attention
since the pathogenesis of a disease might have different bases
in different racial population groups.Acknowledgement
We thank the patients for their kind participation in our study.
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